Year: 2022 | Month: April | Volume 12 | Issue 2
Imatinib in the Management of Canine Cutaneous Mast Cell Tumours
K. Jeyaraja
K. Sesha Saikrishna
D. Sumathi
N. Pazhanivel
DOI:10.30954/2277-940X.02.2022.3
Abstract:
Mast cell tumours are one of the commonly recorded cutaneous tumours in dogs which are seen as either solitary lesion or diffused ones. The present case study discusses about the use of tyrosine kinase inhibitor i.e., Imatinib mesylate in the management of cutaneous mast cell tumours in seven dogs presented to Madras Veterinary Teaching Hospital with cutaneous ulcerations, nodular lesions and exudation. Fine needle aspiration cytology and tissue biopsy were done to confirm the diagnosis of cutaneous mast cell tumours. All the case were treated with tyrosine kinase inhibitor i.e., Tab.Imatinib @10 mg/kg orally SID for 10 weeks along with Tab. Prednisolone @1 mg/kg SID orally for three weeks followed by tapering of the dose to 0.5 mg/kg in fourth week. Chlorpheniramine maleate @3 mg/kg SID and famotidine @ 0.5 mg/kg BID were also added to the protocol. Out of seven cases treated, four showed significant improvement by 5th week while two showed partial remission and one did not respond. Thrombocytopaenia, Anaemia and ulcerative gastritis were the complications seen during the therapy.
Highlights
- Study on tyrosine kinase inhibitor Imatinib in treatment of canine cutaneous mast cell tumours
- Imatinib was found to have good success in treating mast cell tumours with minimal side effects.
© This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited
Print This Article Email This Article to Your Friend
